Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) | |
US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 26, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 26, 2025 |
Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient
NCE-1 date: 2022-01-26
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9375498 | AAA USA INC | Process for the preparation of complexes of 68Ga |
Aug, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 1, 2023 |
Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient
Market Authorisation Date: 01 June, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic